Ladenburg Thalmann Assumes Corvus Pharmaceuticals (CRVS) at Buy
Tweet
Share
E-mail
Get Alerts CRVS Hot Sheet
Price: $14.46 +0.91%
Rating Summary:
14 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
14 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Ladenburg Thalmann analyst Kevin DeGeeter assumes coverage on Corvus Pharmaceuticals (NASDAQ: CRVS) with a Buy rating and a price target of $32.00.
For an analyst ratings summary and ratings history on Corvus Pharmaceuticals click here. For more ratings news on Corvus Pharmaceuticals click here.
Shares of Corvus Pharmaceuticals closed at $13.31 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Sigma Lithium resumes full operations after signing TAC agreement
- QSE closes $6M private placement with final tranche of $674K
Create E-mail Alert Related Categories
New CoverageRelated Entities
Ladenburg Thalmann Financial Services, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
